BioNTech’s PD-L1xVEGF antibody has shown an impressive rate of one-year survival when used first-line for a serious form of lung cancer. If results stay consistent in larger trials, this approach could become the standard of care.
关于我们
Endpoints is the biopharma world's leading source for breaking news, smart analysis and exclusive access. We cover the intersection of science, money and power in the world's most innovative industry, and are a part of the Financial Times' FT Specialist group.
- 网站
-
https://endpts.com
Endpoints News的外部链接
- 所属行业
- 在线音视频媒体
- 规模
- 51-200 人
- 总部
- Lawrence，KS
- 类型
- 私人持股
- 创立
- 2014
- 领域
- Biotechnology、News、Drug Development和Pharmaceuticals
地点
-
主要
获取路线
W 24th Pl
US，KS，Lawrence，66049
Endpoints News员工
动态
-
Novo Nordisk announces up to $1B deal with Texas-based Lexicon Pharmaceuticals, Inc. to access its oral small molecule obesity drug. https://lnkd.in/euSD9xvj
-
Our reporters are closely covering the restructuring across HHS, have you got a tip or something to share? Max Bayer wants to hear from you.
If you're an employee at a federal health agency, especially if you work in drug regulation or research into new therapies, please keep me in mind if there's a story worth getting out there. The Endpoints News team is closely covering the restructuring across HHS, and our scrappy newsroom has broken a number of stories in the administration's first two months. My colleague Zachary Brennan has been on top of all things FDA. Nicole DeFeudis closely covers IRA drug negotiations. And I'm focusing on vaccine policy, ASPR and pandemic preparedness. Our team has covered dozens and dozens of private sector RIFs just in the last few years and we know how to handle these stories with sensitivity and care. We're not interested in pressuring information from anyone. My email is [email protected] and my Signal is maxbayer.10 #sources #HHS #CDC #FDA #CMS #ASPR #opentowork #federalemployees #DOGE #layoffs
-
We're seeking nominations for Endpoints News' fourth annual report on LGBTQ+ leaders in the biopharma industry. The deadline to nominate somebody is Monday, March 31. More details in the link below and nomination form in the comments. #biotechindustry #biotechlgbtq #lgbtqleaders https://lnkd.in/g33Vd3QB
Founded Endpoints News -- 230,000 subscribers -- invented FierceBiotech. 47 years in journalism. Now devoting a lot of my time to fending off Merkel cell carcinoma. We'll see.
In our own small way we're continuing to embrace a diverse, welcoming biopharma industry that understands that the best organizations reach out, not cut off and threaten. Join us. https://lnkd.in/dTf_R2Ah
-
So excited to share the Endpoints News Health Tech newsletter's been named a finalist for a 2025 Neal Award! Endpoints picked up three finalist spots, for the newsletter (Ngai Yeung + Shelby Livingston), for Andrew Dunn's work covering AI in drug research, and Jared Whitlock/Max Bayer/Ryan Cross's reporting on the risks and rewards within drug development!
-
-
Miga Health's co-founders decided to sell instead of building on their success. Lydia Ramsey Pflanzer, head of Endpoints Health Tech newsletter, finds out why that worked for the cardiovascular care start-up. https://lnkd.in/ez7i4yue
-
New: Genetic medicines company ElevateBio has reduced headcount by about 17%, a spokesperson confirmed to Endpoints News. It's the third round of layoffs since the fall of 2023. Almost 400 employees remain at the startup, which is one of the most well-funded private cell & gene therapy biotechs. It's raised more than $1.2 billion and forged collaborations with Novo Nordisk, Moderna, Affini-T and others over the years. “Despite significant headwinds in the biotech and genetic medicine sectors, ElevateBio has grown revenues by more than 200% over the past two years,” the spokesperson said. “To ensure long-term success and our ability to scale, we took proactive steps to reduce a portion of our workforce across ElevateBio and Life Edit.” #elevatebio #lifeedittherapeutics #basecamp #cellandgenetherapy #crispr #geneticmedicines #northcarolinabiotech #biotechlayoffs
-
NEW: Greg Kunst, a founder and CEO of Aurion Biotech, has been pushed out of the cell therapy startup, in the latest escalation of a battle between Aurion and its the eye giant Alcon. The Seattle-based biotech and Alcon have battling in court since November, as Alcon objected to Aurion's IPO plans. Aurion countered that Alcon was trying to acquire the startup on the cheap by blocking its financing plans. On Wednesday, Alcon said it now has a majority stake in Aurion and has replaced Kunst. My latest for Endpoints News:
-
Kennedy announces 10,000 job cuts at HHS, including thousands of positions at FDA, NIH and CDC, as he reorganizes the health department. https://lnkd.in/efCRx7Uw